Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CNTA 
Centessa Pharmaceuticals PLC ADR (CNTA)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CNTA (5-star) is a STRONG-BUY. BUY since 5 days. Simulated Profits (-6.08%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $32.42
1 Year Target Price $32.42
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 121.93% | Avg. Invested days 41 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.95B USD | Price to earnings Ratio - | 1Y Target Price 32.42 |
Price to earnings Ratio - | 1Y Target Price 32.42 | ||
Volume (30-day avg) 11 | Beta 1.48 | 52 Weeks Range 9.60 - 23.24 | Updated Date 09/16/2025 |
52 Weeks Range 9.60 - 23.24 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1376.1% |
Management Effectiveness
Return on Assets (TTM) -28.96% | Return on Equity (TTM) -72.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2791558639 | Price to Sales(TTM) 196.82 |
Enterprise Value 2791558639 | Price to Sales(TTM) 196.82 | ||
Enterprise Value to Revenue 186.1 | Enterprise Value to EBITDA 1.12 | Shares Outstanding 134073000 | Shares Floating 84877870 |
Shares Outstanding 134073000 | Shares Floating 84877870 | ||
Percent Insiders 0.49 | Percent Institutions 93.69 |
Upturn AI SWOT
Centessa Pharmaceuticals PLC ADR
Company Overview
History and Background
Centessa Pharmaceuticals PLC ADR was formed in 2021 through the merger of ten private biotech companies. The aim was to diversify risk and leverage a broader pipeline of drug candidates.
Core Business Areas
- Oncology: Development of novel cancer therapies targeting various tumor types.
- Hematology: Development of treatments for blood disorders.
- Immunology: Development of immunomodulatory therapies for autoimmune diseases.
- Neuroscience: Development of treatments for neurological disorders.
Leadership and Structure
The company is led by a board of directors and a management team with experience in pharmaceutical development and commercialization. The structure is organized around therapeutic areas.
Top Products and Market Share
Key Offerings
- Imbruvica (Ibrutinib) - Royalty: While Centessa doesn't directly sell Imbruvica, they receive royalties on sales. Competitors include other BTK inhibitors like Calquence (AZN) and Brukinsa (BGBI).
- Various Early-Stage Clinical Programs: Centessa has a diverse pipeline of early-stage clinical programs across oncology, hematology, immunology, and neuroscience. These programs are in early stages and do not yet have market share.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and intense competition. Trends include personalized medicine, gene therapy, and immunotherapy.
Positioning
Centessa aims to differentiate itself through its diversified pipeline and focus on innovative therapies.
Total Addressable Market (TAM)
The TAM for Centessa's target indications spans multiple therapeutic areas potentially reaching hundreds of billions of dollars, depending on clinical success and market penetration.
Upturn SWOT Analysis
Strengths
- Diversified pipeline
- Experienced management team
- Strong scientific expertise
- Potential for breakthrough therapies
Weaknesses
- Early-stage pipeline (high risk)
- Dependence on clinical trial success
- Limited revenue generation
- Cash burn rate
Opportunities
- Partnerships and collaborations
- Acquisition of promising assets
- Expansion into new therapeutic areas
- Accelerated regulatory pathways
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established players
- Patent expirations
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- NVS
- MRK
- AZN
Competitive Landscape
Centessa is a small player compared to established pharmaceutical giants. Its competitive advantage lies in its diversified pipeline and potential for innovative therapies.
Growth Trajectory and Initiatives
Historical Growth: Centessa's historical growth is characterized by pipeline development and investment in R&D.
Future Projections: Future growth depends on the success of its clinical programs and regulatory approvals. Analyst estimates vary widely depending on these factors.
Recent Initiatives: Recent initiatives include advancing key clinical programs, securing partnerships, and optimizing the development pipeline.
Summary
Centessa Pharmaceuticals PLC ADR is an early-stage biopharmaceutical company with a diversified pipeline and the potential for significant growth. However, it faces substantial risks associated with clinical trial success, regulatory approvals, and competition. The company's financial performance is currently reliant on funding rather than product sales. Investors should monitor clinical trial results and financial management closely.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC)
- Analyst reports
- Company website
- Publicly available financial data
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share data are estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Centessa Pharmaceuticals PLC ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-05-28 | CEO & Director Dr. Saurabh Saha M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 98 | Website https://centessa.com |
Full time employees 98 | Website https://centessa.com | ||
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines. Its lead clinical-stage program includes ORX750, an orally administered OX2R agonist in a Phase 2a study for the treatment of idiopathic hypersomnia and narcolepsy type 1 and 2. The company also develops ORX142 for the treatment of neurological and neurodegenerative disorders, as well as other potential symptoms, including excessive daytime sleepiness, impaired attention, cognitive deficits, and fatigue; and ORX489 for the treatment of neuropsychiatric disorders. In addition, it offers LockBody, which is designed to selectively drive potent effector function activity, such as CD3, into the tumor microenvironment. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.